NASDAQ$IMRX
Immuneering Corporation · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Immuneering Corporation reported financial results for the second quarter ended June 30, 2026.
The company reported a net loss of $17.3 million for the quarter, driven by R&D expenses of $14.0 million and G&A expenses of $5.0 million. Cash, cash equivalents and marketable securities totaled $182.7 million at quarter end, supporting ongoing clinical development of atebimetinib.
- Net loss of $17.3 million for Q2 2026, compared to $14.4 million in Q2 2025.
- R&D expenses increased to $14.0 million, reflecting advancement of MAPKeeper 301 trial.
- Strong liquidity position with $182.7 million in cash and marketable securities.
- Continued progress on atebimetinib clinical programs with anticipated milestones in 2026-2028.
Headline financials
Revenue & EPS history
Immuneering · Revenue · Quarterly
$0
Forward guidance
Company expects to dose first patient in NSCLC combination trial in H2 2026, provide additional preclinical data in Q4 2026, begin IND-enabling studies in mid-2027, and report topline data from MAPKeeper 301 in mid-2028.
Tailwinds
- Strong cash runway into 2029
- Positive interim data from Phase 2a atebimetinib trial
- Fast track designations received for multiple indications
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-4.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+3.7%
Avg return
30 days after
23%
5 / 22 earnings
Positive
+8.3%
Q4 2022
Best reaction
-13.0%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | +6.8% | +13.5% | +9.4% | |
| Q3 2025 | -2.4% | +8.0% | -8.2% | |
| Q1 2025 | +4.9% | +0.7% | +64.6% | |
| Q4 2024 | -1.8% | +0.6% | -24.4% | |
| Q3 2024 | +6.0% | -1.6% | -10.7% | |
| Q2 2024 | -6.6% | -10.7% | -2.5% | |
| Q1 2024 | -1.2% | -12.1% | -14.5% | |
| Q4 2023 | -0.8% | +3.2% | -53.4% | |
| Q3 2023 | -12.1% | -10.8% | +24.9% | |
| Q2 2023 | -2.2% | -6.4% | -15.7% | |
| Q1 2023 | -9.3% | -11.2% | -0.6% | |
| Q4 2022 | +8.3% | +47.9% | +64.2% | |
| Q3 2022 | -12.5% | -16.3% | -40.1% | |
| Q2 2022 | -5.7% | -1.5% | +32.2% | |
| Q1 2022 | +3.0% | +17.2% | +49.9% | |
| Q4 2021 | -7.3% | -6.3% | +1.0% | |
| Q3 2021 | -5.4% | -10.2% | -29.5% | |
| Q3 2020 | -5.4% | -10.2% | -29.5% | |
| Q2 2021 | -13.0% | +8.5% | +16.2% | |
| Q1 2021 | -13.0% | +8.5% | +16.2% | |
| Q4 2020 | -13.0% | +8.5% | +16.2% | |
| Q2 2020 | -13.0% | +8.5% | +16.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro